The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 43 | Exploring the challenges of limited druggable targets in gastric cancer compared to lung cancer
Mitsuru Sasako, MD, PhD, Yodogawa Christian Hospital, Osaka, Japan, discusses the difference in druggable targets between lung and gastric cancers. While approximately half of lung cancers have druggable targets identifiable through molecular analysis, gastric cancer has far fewer, limiting treatment options due to the disease’s heterogeneity. Despite this challenge, Dr Sasako emphasizes the importance of continued research and not giving up. This interview took place at the ESSO 43 congress in Antwerp, Belgium.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
